Tags

Type your tag names separated by a space and hit enter

Antivirals--current trends in fighting influenza.
Acta Biochim Pol. 2014; 61(3):495-504.AB

Abstract

Influenza virus infection is a major source of morbidity and mortality worldwide. Due to the variable effectiveness of existing vaccines, especially in the early stages of an epidemic, antiviral drugs represent the first line of defense against the virus. Currently, there are two major classes of anti-influenza drugs approved by the FDA for clinical use: M2 protein inhibitors (amantadine and rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir). However, increasing resistance to these available influenza antivirals among circulating influenza viruses highlights the need to develop alternative approaches for the prevention and/or treatment of influenza. This review presents an overview of currently available drugs for influenza treatment as well as summarizes some new antiviral strategies that are now being tested covering agents targeting both the viral proteins and the host-virus interaction. We discuss their mechanisms of action, resistance and the therapeutic potential as new antiviral drug for use in future influenza pandemics. Additionally, combination therapy based on these drugs is also described.

Authors+Show Affiliations

Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdańsk, Poland.Department of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdańsk, Poland.Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdańsk, Poland.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25180220

Citation

Król, Ewelina, et al. "Antivirals--current Trends in Fighting Influenza." Acta Biochimica Polonica, vol. 61, no. 3, 2014, pp. 495-504.
Król E, Rychłowska M, Szewczyk B. Antivirals--current trends in fighting influenza. Acta Biochim Pol. 2014;61(3):495-504.
Król, E., Rychłowska, M., & Szewczyk, B. (2014). Antivirals--current trends in fighting influenza. Acta Biochimica Polonica, 61(3), 495-504.
Król E, Rychłowska M, Szewczyk B. Antivirals--current Trends in Fighting Influenza. Acta Biochim Pol. 2014;61(3):495-504. PubMed PMID: 25180220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antivirals--current trends in fighting influenza. AU - Król,Ewelina, AU - Rychłowska,Małgorzata, AU - Szewczyk,Bogusław, Y1 - 2014/09/01/ PY - 2014/05/27/received PY - 2014/08/07/revised PY - 2014/08/26/accepted PY - 2014/9/3/entrez PY - 2014/9/3/pubmed PY - 2015/1/1/medline SP - 495 EP - 504 JF - Acta biochimica Polonica JO - Acta Biochim. Pol. VL - 61 IS - 3 N2 - Influenza virus infection is a major source of morbidity and mortality worldwide. Due to the variable effectiveness of existing vaccines, especially in the early stages of an epidemic, antiviral drugs represent the first line of defense against the virus. Currently, there are two major classes of anti-influenza drugs approved by the FDA for clinical use: M2 protein inhibitors (amantadine and rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir). However, increasing resistance to these available influenza antivirals among circulating influenza viruses highlights the need to develop alternative approaches for the prevention and/or treatment of influenza. This review presents an overview of currently available drugs for influenza treatment as well as summarizes some new antiviral strategies that are now being tested covering agents targeting both the viral proteins and the host-virus interaction. We discuss their mechanisms of action, resistance and the therapeutic potential as new antiviral drug for use in future influenza pandemics. Additionally, combination therapy based on these drugs is also described. SN - 1734-154X UR - https://www.unboundmedicine.com/medline/citation/25180220/Antivirals__current_trends_in_fighting_influenza_ L2 - http://www.actabp.pl/pdf/3_2014/495.pdf DB - PRIME DP - Unbound Medicine ER -